Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-16T14:54:03.118Z Has data issue: false hasContentIssue false
  • English
  • Français

Contributions of GABAA Receptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep Disorders

Published online by Cambridge University Press:  07 November 2014

Nancy A. Ator
Get access Rights & Permissions [Opens in a new window]

Abstract

When benzodiazepines (BZs) supplanted barbiturates as a favored, safer treatment for anxiety and sleep disorders in the 1960s, the abuse liability and dependence potential of these drugs were little understood. Widespread recognition of the difficulty of stopping use of chronically taken BZs emerged through the popular press in the late 1970s, which resulted in reluctance to prescribe these otherwise clinically useful compounds. Evolution of the understanding of the biochemical basis for BZ effects in the 1980s and 1990s, coupled with regulatory emphasis on collection of data used in legal scheduling decisions, made possible a targeted search for drugs that would provide effective treatment for anxiety disorders in the absence of abuse liability or dependence potential. Compounds that have selective efficacy at subtypes of the γ-aminobutyric acid type A receptor, are active in preclinical anxiolytic screens, but negative in preclinical studies of behavior relevant to evaluation of abuse liability appear to be one promising means for achieving this end.

Type
Review Article
Information
CNS Spectrums , Volume 10 , Issue 1 , January 2005 , pp. 31 - 39
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Rall, TW. Hypnotics and sedatives: ethanol. In: Gilman, AG, Rall, TW, Nies, AS, Taylor, P, eds. The Pharmacological Basis of Therapeutics. New York, NY: Pergamon Press; 1990:345–382.Google Scholar
2. Alexander, EJ. Withdrawal effects of sodium amytal. Dis Nerv Syst. 1951;12:77–82.Google Scholar
3. Isbell, H, Altschul, S, Kornetsky, CH, Eisenman, AJ, Flanary, HG, Fraser, HF. Chronic barbiturate intoxication: an experimental study. Arch Neurol Psychiatry. 1950;64:1–28.Google Scholar
4. Jaffe, JH, Sharpless, SK. The rapid development of physical dependence on barbiturates. J Pharmacol Exp Ther. 1965;150:140–145.Google Scholar
5. Gordon, B. I'm Dancing as Fast as I Can. New York, NY: Harper & Row; 1979.Google Scholar
6. Use and misuse of benzodiazepines. Hearing before the Subcommittee on Health and Scientific Research of the Committee on Labor and Human Resources, United States Senate, 96th Congress 1979; 1.Google Scholar
7. Nutt, DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 2005;10:49–56.CrossRefGoogle ScholarPubMed
8. Schwartz, KL, Margolis, S. Depression and Anxiety. The Johns Hopkins White Papers. New York, NY: Medletter Associates; 2003.Google Scholar
9. Tyrer, P. Dependence as a limiting factor in the clinical use of minor tranquillizers. Pharmacol Ther. 1988;36:173–188.Google Scholar
10. Woods, JH. Problems and opportunities in regulation of benzodiazepines. J Clin Pharmacol. 1998;38:773–782.CrossRefGoogle ScholarPubMed
11. Squires, RF, Braestrup, C. Benzodiazepine receptors in rat brain. Nature. 1977;266:732–734.Google Scholar
12. Squires, RF, Benson, DI, Braestrup, C, et al. Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol Biochem Behav. 1979;10:825–830.Google Scholar
13. Denis, T, Dubois, A, Benavides, J, Scatton, B. Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H] flunitrazepam and the omega 1 selective ligand [3H]zolpidem. J Pharmacol Exp Ther. 1988;247:309–322.Google Scholar
14. Dubnick, B, Lippa, AS, Klepner, CA, Coupet, J, Greenblatt, EN, Beer, B. The separation of 3H-benzodiazepine binding sites in brain and of benzodiazepine pharmacological properties. Pharmacol Biochem Behav. 1983;18;311–318.Google Scholar
15. Langtry, HD, Benfield, P. Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs, 1990;40:291–313.Google Scholar
16. Griebel, G, Perrault, G, Sanger, DJ. Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. J Psychopharmacol. 1998;12:356–365.Google Scholar
17. Beer, B, Clody, DE, Mangano, R, Levner, M, Mayer, P, Barrett, JE. A review of the preclinical development of zaleplon, a novel non-benzodiazepine hypnotic for the treatment of insomnia. CNS Drug Rev. 1997;3:207–224.Google Scholar
18. Dawson, GR. Development of subtype selective GABAA potentiators. CNS Spectr. 2005;10:21–27.Google Scholar
19. McKernan, RM, Rosahl, TW, Reynolds, DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor al subtype. Nat Neurosci. 2000;3:587–592.CrossRefGoogle ScholarPubMed
20. Hollister, LE, Motzenbecker, FP, Degan, RO. Withdrawal reactions from chlordiazepoxide (“Librium”). Psychopharmacologia. 1961;2:63–68.Google Scholar
21. World Health Organization. Guideline for the WHO review of dependence producing psychoactive substances for international control. Available at: http://www.who.int/medicines/library/qsm/who-edm-qsm-2000-5/who-edm-qsm-000-5.shtml. Accessed on December 12, 2004.Google Scholar
22. WHO Expert Committee on Drug Dependence. Thirty-Second Report. Geneva, Switzerland: World Health Organization; 2001. Technical Report Series 903.Google Scholar
23. Balster, RL, Bigelow, GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003;70:S13–S40.Google Scholar
24. Spillane, J, McAllister, WB. Keeping the lid on: a century of drug regulation and control. Drug Alcohol Depend. 2003;70:S5–S12.CrossRefGoogle ScholarPubMed
25. Arfken, CL, Cicero, TJ. Postmarketing surveillance for drug abuse. Drug Alcohol Depend. 2003;70;S97–S105.Google Scholar
26. Ator, NA, Griffiths, RR. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend. 2003;70:S55–S72.CrossRefGoogle ScholarPubMed
27. Rush, CR, Ator, NA, Simpson, CA, Bickel, WK. Behavioral pharmacology of commonly abused drugs: concordance between laboratory studies conducted with animals and humans. In: Carroll, ME, Overmier, JB, eds. Animal Research and Human Health. Washington DC: American Psychological Association; 2001:101–114.Google Scholar
28. Lelas, S, Spealman, RD, Rowlett, JK. Using behavior to elucidate receptor mechanisms: a review of the discriminative stimulus effects of benzodiazepines. Exp Clin Pyschopharmacol. 2000;8:294–311.Google Scholar
29. Sannerud, CA, Ator, NA, Griffiths, RR. Comparison of the discriminative stimulus effects of midazolam after intracerebroventricular and peripheral administration in the rat. Life Sci. 1991;49:261–268.Google Scholar
30. Mansbach, RS, Barrett, JE. Discriminative stimulus properties of buspirone in the pigeon. J Pharmacol Exp Ther. 1987;240:364–369.Google Scholar
31. Ator, NA. Discriminative stimulus effects of the novel anxiolytic buspirone. Behav Pharmacol. 1991;2:3–14.Google Scholar
32. Ator, NA, Griffiths, RR. Selectivity in the generalization profile in baboons trained to discriminate lorazepam: benzodiazepines, barbiturates and other sedative/anxiolytics. J Pharmacol Exp Ther. 1997;282:1442–1457.Google ScholarPubMed
33. Ator, NA, Griffiths, RR. Drug discrimination analysis of partial agonists at the benzodiazepine site. I. Differential effects of U-78875 across training conditions in baboons and rats. J Pharmacol Exp Ther. 1999;289:1434–1446.Google Scholar
34. Okamoto, M, Boisse, NR. Sedative-hypnotic tolerance and physical dependence. Trends Pharmacol Sci. 1981;2:9–13.Google Scholar
35. Yutrezenka, GJ. Intensity of the withdrawal syndrome varies with duration of pentobarbital administration. Pharmacol Biochem Behav. 1989;34:49–51.Google Scholar
36. Lamb, RJ, Griffiths, RR. Effects of Ro 15-1788 and CGS 8216 in diazepam-dependent baboons. Eur J Pharmacol. 1987;143:205–212.Google Scholar
37. Woods, JH, Katz, JL, Winger, G. Abuse liability of benzodiazepines. Pharmacol Rev. 1987;39:251–419.Google ScholarPubMed
38. Yutrzenka, GJ, Patrick, GA, Rosenberger, W. Substitution of psychoactive drugs in pentobarbital-dependent rats. Drug Alcohol Depend. 1989;26:9–17.Google Scholar
39. Lukas, SE, Griffiths, RR. Precipitated withdrawal by a benzodiaepine receptor antagonist (Ro 15-1788) after 7 days of diazepam. Science. 1982;217:1161–1163.Google Scholar
40. Yanagita, T, Takahashi, S. Development of tolerance to and physical dependence on barbiturates in rhesus monkeys. J Pharmacol Exp Ther. 1970;172:163–169.Google Scholar
41. Lader, MH. Benzodiazepine dependence. ISI Atlas of Science: Pharmacology. Philadelphia, Penn: ISI Press; 1987:299–302.Google Scholar
42. Higgit, A, Fonagy, P. Benzodiazepine dependence syndromes and syndromes of withdrawal. In: Hallstrom, C, ed. Benzodiazepine Dependence. New York, NY: Oxford University Press. 1993:58–70.Google Scholar
43. Weerts, EM, Ator, NA, Grech, DM, Griffiths, RR. Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J Pharmacol Exp Ther. 1998;285:41–53.Google Scholar
44. Griffiths, RR, Lamb, RJ, Sannerud, CA, Ator, NA, Brady, JV. Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology (Berl). 1991;103:154–161.Google Scholar
45. Balster, RL, Woolverton, WL. Intravenous buspirone self-administration in rhesus monkeys. J Clin Psychiatry. 1982;43:34–37.Google Scholar
46. Sannerud, CA, Ator, NA, Griffiths, RR. Methocarbamol: evaluation of reinforcing and discriminative stimulus effects. Behav Pharmacol. 1991;2:143–150.Google Scholar
47. Griffiths, RR, Sannerud, CA, Ator, NA, Brady, JV. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther. 1992;260:1199–1208.Google Scholar
48. Ator, NA. Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons. Drug Alcohol Depend. 2000;61:55–68.CrossRefGoogle ScholarPubMed
49. Griffiths, RR, Lukas, SE, Bradford, LD, Brady, JV, Snell, JD. Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology (Berl). 1981;75:101–109.CrossRefGoogle ScholarPubMed
50. Ator, NA, Weerts, EM, Griffiths, RR. Self-injection of flunitrazepam alone and in the context of methadone maintenance in baboons. Drug Alcohol Depend. In press.Google Scholar
51. Ator, NA, Weerts, EM, Kaminski, BJ, Kautz, MA, Griffiths, RR. Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. Drug Alcohol Depend. 2000;61:69–84.Google Scholar
52. Von Voigtlander, PF, Lewis, RA. A rapid screening method for the assessment of benzodiazepine receptor-related physical dependence in mice. Evaluation of benzodiazepine-related agonists and partial agonists. J Pharmacol Methods. 1991;26:1–5.Google Scholar
53. Perrault, G, Morel, E, Sanger, DJ, Zivkovic, B. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic Zolpidem. Pharmacol Exp Ther. 1992;263:298–303.Google Scholar
54. Cavallaro, R, Regazzetti, MG, Covelli, G, Smeraldi, E. Tolerance and withdrawal with Zolpidem. Lancet. 1993;342:374–375.Google Scholar
55. Watsky, E. Management of Zolpidem withdrawal. J Clin Psychopharmacol. 1996;16:459.Google Scholar
56. Bottlender, R, Schütz, B, Möller, H-J, Soyka, M. Zolpidem dependence in a patient with former polysubstance abuse. Pharmacopsychiatry. 1997;30:108.Google Scholar
57. Aragona, M. Abuse, dependence, and epileptic seizures after Zolpidem withdrawal: review and case report. Clin Neuropharmacol. 2000;23:281–283.Google Scholar
58. Walsh, JK, Roth, T, Randazzo, A, et al. Eight weeks of non-nightly use of Zolpidem for primary insomnia. Sleep. 2000;23:1087–1096.Google Scholar
59. Griffiths, RR, Bigelow, GE, Ator, NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003;70:S41–S54.Google Scholar
60. Griffiths, RR, Bigelow, GE, Liebson, I, Kaliszak, JE. Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther. 1980;215:649–661.Google Scholar
61. Evans, SM, Funderburk, FR, Griffiths, RR. Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther. 1990;255:1246–1255.Google Scholar
62. Rush, CR, Frey, JM, Griffiths, RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl). 1999;145:39–51.Google Scholar
63. Yanagita, T, Kato, S. Dependence studies on zopiclone. In: Harris, LS, ed. Problems of Drug Dependence, 1982; Proceedings of the 44th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph Series 43. Rockville MD: Department of Health and Human Services; 1983;164–170.Google Scholar
64. Dämgen, K, Lüddens, H. Zaleplon displays a selectivity to recombinant GABA-A receptors different from Zolpidem, zopiclone and benzodiazepines. Neurosci Res Comm. 1999;25:139–148.Google Scholar
65. Ator, NA, Griffiths, RR. Discriminative stimulus effects of atypical anxiolytics in baboons and rats. J Pharmacol Exp Ther. 1986;237:393–403.Google Scholar